Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — TD Cowen Healthcare Conference 2025

32 slides from Eyepoint's conference presentation, Mar 4, 2025

  1. Slide 1: TD Cowen Healthcare Conference Presentation

    TD Cowen Healthcare Conference Presentation March 4, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Confidential Exhibit 99.1

  2. Slide 2: The Leader in Sustained Release Drug Delivery for Retinal Disease

    The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Durasert® features robust safety profile across multiple indications Compelling DAVIO 2 data enabling rapid enrollment of global Phase 3 pivotal trials for DURAVYU in wet AMD S

  3. Slide 3: Multiple Programs Targeting Significant Market Opportunities

    Multiple Programs Targeting Significant Market Opportunities ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Source: Internal estimates based on publicly reported actual and estimated sales data. wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; NPDR, non-prolifer

  4. Slide 4: Pipeline Leveraging Durasert E Drug Delivery Technology

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; PK, pharmacokinetic; GA, geographic atrophy Pipeline Leveraging Durasert E™ Drug Delivery Technology trial underway non-clinical Durasert E™ Programs Indication Disco

  5. Slide 5: DURAVYU: Vorolanib in Durasert E

    IVT, intravitreal; TIE2, tyrosine-protein kinase receptor TIE-2; VEGF(R), vascular endothelial growth factor (receptor). DURAVYUTM (EYP-1901): Vorolanib in Durasert ETM Durasert E™ Bioerodible, sustained IVT drug delivery Vorolanib Patented and potent receptor tyrosine kinase inhibitor (TKI): select

  6. Slide 6: DURAVYU Demonstrated Positive Efficacy and Favorable Safety Across Multiple Trials

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials and Indications 1. Data as of January 16, 2025. Preliminary data pending final analysis. Wet AMD, wet age-related macular degeneration; NPDR,

  7. Slide 7: LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD NON-INFERIORITY VERSUS AN AFLIBERCEPT CONTROL

  8. Slide 8: DAVIO 2 Results - All Primary and Secondary Endpoints Met

    ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Ongoing DURAVYU Phase 3 Trials in Wet AMD Supported by Phase 2 DAVIO 2 Results - All Primary and Secondary Endpoints Met Endpoint 2mg 3mg R Primary: Non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Favorabl

  9. Slide 9: Phase 3 Pivotal Trials Designed to Evaluate Non-Inferiority vs. Aflibercept

    Phase 3 Pivotal Trials Designed to Evaluate Non-Inferiority of DURAVYU vs. Aflibercept Control ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening D1 W4 W8 W12 W16 W24 W32 W84-W92 W20 W28 DURAVYU™ 2.7mg Aflibercept 2mg q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHE

  10. Slide 10: Phase 3 Trials in wet AMD Seeing Exceptional Enrollment Rates

    Phase 3 Clinical Trials for DURAVYU in wet AMD Seeing Exceptional Enrollment Rates Driven by Significant Investigator and Patient Enthusiasm ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. June 2024 Final Phase 3 protocols October 2024 First patient in LUGANO trial dosed December 2024 Firs

  11. Slide 11: State-Of-The-Art cGMP Manufacturing Facility in Northbridge

    State-Of-The-Art cGMP Manufacturing Facility in Northbridge Ready to Support DURAVYU through Phase 3 and Global Commercial Production ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. cGMP, current good manufacturing practices; FDA, Federal Drug Administration; EMA, European Medicines Agency

  12. Slide 12: Phase 2 VERONA Clinical Trial in DME

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME 24 Week results DME, diabetic macular edema Data as of January 16, 2025. Preliminary data pending final analysis.

  13. Slide 13: Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need

    Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. William R. Rowley, Clement Bezold, Yasemin Arikan, et al. Diabetes 2030: Insights from Yesterday, Today and Future Trends. PubMed Cent

  14. Slide 14: DURAVYU Positioned to Provide Improved DME Treatment Paradigm

    DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm Compared to Current Anti-VEGF Therapies ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 24-Month Treatment Regimens for DME: 2–4-month dosing 1-4-month dosing Anti-VEGF SoC DURAVYU™ (vorolanib intravitreal insert)

  15. Slide 15: VERONA Phase 2 Clinical Trial Design in DME

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; VEGF, vascular endothelial growth factor; BCVA, best corrected visual acuity; OCT, optical coherence tomography; CST, central subfield thickness DURAVYU dosing Visit Scheduled aflibercept injection Sham injection

  16. Slide 16: VERONA Clinical Trial Supplement Criteria

    VERONA Clinical Trial Supplement Criteria ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. vs. best on study measurement; 2. as measured by Spectral domain OCT (SD-OCT) BCVA, best corrected visual acuity; PRN, pro re nata; CST, central subfield thickness Starting at Week 4: Reduction in

  17. Slide 17: VERONA: Phase 2 Clinical Trial Met Primary and Key Secondary Endpoints

    VERONA: Phase 2 Clinical Trial Met Primary and Key Secondary Endpoints Data supports DURAVYU as a Potential Treatment for DME with improvement in vision and anatomy with superior dosing intervals ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg: Primary endpoint achieved - ext

  18. Slide 18: Phase 2 VERONA Clinical Trial in DME – 24-Week Results

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME – 24-Week Results DME, diabetic macular edema Data as of January 16, 2025. Preliminary data pending final analysis.

  19. Slide 19: Primary Endpoint Met - Greater Proportion of Supplement-Free Eyes

    Primary Endpoint Met - Patients Treated with DURAVYU had a Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control at 24-Weeks ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of January 16, 2025. Preliminary data pending final analysis. 2.7mg DURAVYU reduced treatment bu

  20. Slide 20: Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Improvement in BCVA

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA; Supports Noninferiority in Pivotal Trial BCVA, best-corrected visual acuity; VA, visual acuity Data as of January 16, 2025. Preliminary data pending final

  21. Slide 21: Excluding a Single Outlier Patient, DURAVYU 2.7mg Improved +10 Letters

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Excluding a Single Outlier Patient, DURAVYU 2.7mg Improved +10 Letters vs. Baseline; Nearly +3 Letters Better than Control BCVA, best-corrected visual acuity; VA, visual acuity Data as of January 16, 2025. Preliminary data pending final analy

  22. Slide 22: DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy with 74% More Drying than Aflibercept Control CST: central subfield thickness Data as of January 16, 2025. Preliminary data pending final analysis. Source: Independent reading center

  23. Slide 23: VERONA Sub-Group Analysis of Patients Supplement-free at 24 Weeks

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME Sub-Group Analysis Of Patients Supplement-free at 24 Weeks DME, diabetic macular edema Data as of January 16, 2025. Preliminary data pending final analysis.

  24. Slide 24: Sub-Group Analysis: Better Visual Acuity vs. Control

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Sub-Group Analysis of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU 2.7mg had Better Visual Acuity vs. Control BCVA, best-corrected visual acuity; VA, visual acuity Data as of January 16, 2025. Preliminary data pending final

  25. Slide 25: Sub-Group Analysis: More and Maintained Drying than Control

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Sub-Group Analysis of Supplement-Free Patients* Demonstrated Eyes Treated with DURAVYU 2.7mg had Significantly More and Maintained Drying than Control CST: central subfield thickness Data as of January 16, 2025. Preliminary data pending final

  26. Slide 26: DURAVYU Treated Eyes Well-Controlled vs. Aflibercept in Sub-Group

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Treated Eyes were Well-Controlled at 24 Weeks versus Aflibercept Control in Supplement-Free Patient Sub-Group Absence of DME is defined as CST reading ≤325 microns at 24 weeks. Data as of January 16, 2025. Preliminary data pending fin

  27. Slide 27: VERONA Case Study - Rapid Drying with Improved Vision

    VERONA Clinical Trial Case Study 1 - Rapid Drying with Improved Vision After Single DURAVYU Treatment and No Supplementation ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening BCVA 50 Aflibercept + 2.7mg DURAVYU -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Day1 1 2 3 4 5 6 Eylea Eylea Vab

  28. Slide 28: VERONA Case Study - Continued Drying at Week 24

    VERONA Clinical Trial Case Study 2 - Continued Drying at Week 24 with Improved VA After Single DURAVYU Treatment and No Supplementation ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening BCVA 72 Aflibercept + 2.7mg DURAVYU -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Day1 1 2 3 4 5 6 Avas

  29. Slide 29: VERONA Results Strengthen Robust DURAVYU Safety Database

    VERONA Results Strengthen Robust DURAVYU Safety Database ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SAE, serious adverse event Data as of January 16, 2025. Preliminary data pending final analysis. No reported DURAVYU-related ocular SAEs or systemic SAEs No cases of: Endophthalmitis Re

  30. Slide 30: VERONA: Phase 2 Clinical Trial Summary

    VERONA: Phase 2 Clinical Trial Summary ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of January 16, 2025. Preliminary data pending final analysis. Primary endpoint met for both DURAVYU doses Demonstrated immediate and clinically meaningful results without a full load of afliberce

  31. Slide 31: On Track for Continued Execution And Well-Funded Through Key Milestones

    On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; EOP2, End of Phase 2; wet AMD, wet age-related macular degeneration; SAB, Scientific Advisory Board DURAVYU™ Corporate ✓

  32. Slide 32: TD Cowen Healthcare Conference Presentation

    TD Cowen Healthcare Conference Presentation March 4, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Confidential

EyePoint Pharmaceuticals — TD Cowen Healthcare Conference 2025 on 6ix